The effects of fx-1006a on transthyretin stabilization and clinical outcome measures in patients with v122i or wild-type ttr amyloid cardiomyopathy Endpoint: safety/efficacyPhase 2:interventional, open label, of ttr stabilization, and clinical outcomes in v122i or wildtype ttr amyloid cardiomyopathy. Here, TTR is linked to cardiac amyloidosis.